Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea CrurisAbstract

This study is conducted to compare the efficacy of topical oxiconazole 1% cream versus topical clotrimazole 1% cream in patients with tinea cruris.

Study Overview

• Status: Completed
• Conditions: Tinea Cruris
• Intervention / Treatment: Drug: Topical Oxiconazole cream; Drug: Topical Clotrimazole cream

Detailed Description

Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea Cruris Abstract Objective: To compare the efficacy of topical oxiconazole 1% cream versus topical clotrimazole 1% cream in patients with tinea cruris.

Study Design: Randomized Controlled Trial. Place and Duration of Study: Department of Dermatology, Hayatabad Medical Complex, Peshawar, from Methodology: A total of 386 patients with clinically diagnosed tinea cruris confirmed by potassium hydroxide (KOH) mount were enrolled through consecutive sampling and randomized into two equal groups (n=193 each). Group A received topical clotrimazole 1% cream and Group B received topical oxiconazole 1% cream. Symptoms (pruritus, erythema, vesicles, and desquamation) were graded on a 0-3 scale (total score 0-12) at baseline and at Week 4. Efficacy was defined as ≥50% reduction in total symptom score at Week 4. Data were analyzed using SPSS version 25. Between-group comparisons were performed using appropriate parametric/non-parametric tests and chi-square test, with p≤0.05 considered significant.

Key words: Tinea cruris; Dermatophytosis; Clotrimazole; Oxiconazole; Topical antifungal; Randomized controlled trial; Pruritus; Erythema; Clinical efficacy.

Introduction Dermatophytosis is among the most frequent superficial fungal infections, affecting approximately 20-25% of the global population.¹ It represents a significant health problem, particularly in tropical regions such as Central Asia, where the hot and humid climate favors its occurrence.¹ In Central Asia, the commonest clinical forms include tinea corporis (36-59%) and tinea cruris (12-27%).¹ Although dermatophytosis is not typically fatal, it causes considerable morbidity by interfering with daily activities, reducing quality of life, and increasing healthcare expenditure.

Treatment strategies for dermatophytosis involve the use of systemic or topical antifungal agents. However, topical therapy is generally preferred over oral treatment because it has fewer adverse effects, avoids drug-drug interactions, offers better compliance, and is less costly.² Clotrimazole has been widely used as a topical treatment for tinea corporis/cruris for more than 25 years. Nevertheless, it has drawbacks such as a relatively long treatment duration, which can result in poor compliance and may be associated with higher relapse rates, partly attributed to the rapid emergence of reduced susceptibility.³ To address the growing burden of superficial fungal infections, newer broad-spectrum antifungals such as sertaconazole have expanded available treatment options.⁴ Oxiconazole is a newer topical imidazole antifungal and has been shown in several studies to be more effective than conventional azoles. It allows shorter treatment courses and has been linked with lower relapse rates. It demonstrates both fungistatic and fungicidal activity against dermatophytes. In addition, it provides concomitant symptom control and thus may improve the quality of life of patients with dermatophytosis.⁵

Methodology:

This randomized controlled trial was conducted in the Department of Dermatology, Hayatabad Medical Complex, Peshawar, over a period of six months after approval of the synopsis. Using non-probability consecutive sampling, 386 patients with tinea cruris were enrolled from the dermatology outpatient department after institutional approval and written informed consent. Patients aged 18-60 years of either gender having clinically suspected tinea cruris with positive KOH mount were included. Patients with mixed/extensive fungal infection requiring systemic therapy, other concomitant inflammatory dermatoses involving the groin, known hypersensitivity to azole antifungals, pregnancy or lactation, immunosuppression, and those who had used topical antifungals/corticosteroids or systemic antifungals recently were excluded. Participants were allocated in a 1:1 ratio to Group A (topical clotrimazole 1% cream) or Group B (topical oxiconazole 1% cream) through blocked randomization with allocation concealment using sequentially numbered opaque sealed envelopes; outcome assessment was performed by an assessor blinded to treatment allocation. Both groups were instructed to apply the assigned medication twice daily to the affected area for four weeks. Baseline demographics (age, gender, BMI, duration of complaints, residence, education, profession, and socioeconomic status) were recorded. Clinical severity was assessed at baseline and Week 4 using a standardized symptom score comprising pruritus, erythema, vesicles, and desquamation (each graded 0-3, total score 0-12). Efficacy was defined as ≥50% reduction in total symptom score at Week 4.

• Study Type: Interventional
• Enrollment (Actual): 386
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• Pakistan
  • KPK
    • Peshawar, KPK, Pakistan, 0000
      • Hayatabad medal Complex

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• 18 to 70 years of age
• Both genders
• Patient with diagnosis of tinea crurus as per operational definition

Exclusion Criteria:

• Hypersensitivity to clotrimazole or Oxiconazole
• Uncontrolled diabetes
• Immunosuppresion
• Patient with contact dermatitis

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Group A; Topical Oxiconazole (1%)	Drug: Topical Oxiconazole cream; Group A will recieve topical Oxiconazole
Active Comparator: Group B; Topical Clotrimazole (1%)	Drug: Topical Clotrimazole cream; Group B will recieve topical clotrimazole

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of improvement i	Assessment of change in pruritis by VAS scoring. Assessment of change in erythema on VAS scoring. .	Six months

Collaborators and Investigators

• Sponsor: Hayat Abad Medical Complex, Peshawar
• Investigators: Principal Investigator: Dr Fahad Khan, MTI HMC KPK PESHAWAR

Study record dates

Study Major Dates

• Study Start (Actual): May 15, 2025
• Primary Completion (Actual): October 15, 2025
• Study Completion (Actual): October 15, 2025

Study Registration Dates

• First Submitted: January 29, 2026
• First Submitted That Met QC Criteria: February 25, 2026
• First Posted (Actual): February 27, 2026

Study Record Updates

• Last Update Posted (Actual): February 27, 2026
• Last Update Submitted That Met QC Criteria: February 25, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Tinea
• Additional Relevant MeSH Terms: Infections; Skin Diseases; Bacterial Infections and Mycoses; Skin Diseases, Infectious; Skin Diseases, Eczematous; Dermatitis; Mycoses; Dermatomycoses; Skin and Connective Tissue Diseases; Intertrigo; Tinea; Tinea Cruris
• Other Study ID Numbers: HMCKPK Peshawar

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No